Please assess the completion status of the following clinical trial:

Trial Title: The Use of ARA290 for the Treatment of Diabetic Macular Oedema

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with DR and centre involving DMO with a central subfield thickness of \> 400 microns, as determined using SD-OCT;~2. \>= 18 years of age~3. Clear media and naïve to previous treatments for DMO.~Exclusion Criteria:~1. Macular oedema related to other retinal disease~2. Hazy media that prevents adequate retinal imaging~3. Allergy to fluorescein~4. Previous treatments for DMO~5. DMO with central subfield thickness of \< 400 microns~6. Patients on systemic or topical steroids~7. Use of erythropoiesis stimulating agents within the two months prior to screening or during the trial~8. Treated with any other investigational medication or device within 60 days~9. Pregnant women, women who have not yet reached the menopause (no menses for 12 months or more without an alternative medical cause) who test positive for pregnancy or who are unwilling to take a pregnancy test prior to trial entry or are unwilling to undertake adequate precautions to prevent pregnancy for the duration of the trial.~10. Men who have a female partner and who are unwilling to undertake adequate precautions to prevent pregnancy for the duration of the trial.~11. Female patients who are breastfeeding~12. Active proliferative diabetic retinopathy (PDR) requiring treatment.~13. Patients with other eye diseases besides DR~14. Patients who are unable or unwilling to commit to the study schedule of events~15. Serious illness that is likely to affect the patient's ability to complete the study~Any patient showing a clinically significant improvement between the initial screening and presenting for the first screening/baseline visit may no longer be eligible for the study and will be recorded as a screen failure and will not be entered on to the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: OTHER): Subcutaneous daily injection of ARA 290 at a dose of 4mg for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).